Global Meningococcal Vaccine Market Growth 2026-2032
The global Meningococcal Vaccine market size is predicted to grow from US$ 4047 million in 2025 to US$ 6360 million in 2032; it is expected to grow at a CAGR of 6.6% from 2026 to 2032.
Meningococcal vaccines are preventive biological products designed to generate active immunity against invasive disease caused by Neisseria meningitidis. They are used in routine childhood and adolescent immunization, preventive campaigns, outbreak response, travel vaccination and the protection of medically or occupationally exposed populations. Current marketed serogroup configurations include monovalent MenA, MenB and MenC vaccines; bivalent MenAC and MenBC vaccines; trivalent MenACW vaccines; quadrivalent MenACWY vaccines; and pentavalent MenABCWY and MenACWYX vaccines. MenABCWY is an emerging commercial segment represented by Pfizer?s Penbraya and GSK?s Penmenvy, while MenACWYX is represented by Serum Institute of India?s MenFive. Commercial technology platforms comprise plain polysaccharide vaccines, conjugate vaccines, recombinant protein vaccines and multi-platform products combining conjugate, recombinant protein or outer-membrane-vesicle components.
Upstream supply depends on qualified meningococcal strains, capsular polysaccharides, recombinant antigens, outer-membrane-vesicle antigens, carrier proteins, stabilizers, sterile containers and validated cold-chain packaging. Manufacturing remains concentrated because biological consistency, aseptic processing, analytical comparability, regulatory approval and lot-release testing must be maintained over long production cycles. Downstream purchasers include ministries of health, national immunization programs, international procurement organizations, hospitals, vaccination clinics, pharmacies, travel-health centers, military organizations, universities and occupational-health providers. Public demand is commonly supplied through annual tenders, multi-year framework agreements, stockpile contracts and emergency procurement, while commercial vaccines are distributed through direct supply agreements and specialist health-care channels. Industry gross margin is estimated at approximately 68%, supported by premium-priced conjugate, MenB and pentavalent products but moderated by lower-price public-health procurement.
In the current market, global production of meningococcal vaccines is around 197 million doses, with an average selling price of about 21.00 USD per dose on an EXW basis. Value is more concentrated than physical volume because commercial MenB, MenACWY and MenABCWY vaccines command substantially higher prices than polysaccharide and public-procurement products used extensively in China and the African meningitis belt. The top five suppliers control approximately 84% of global revenue. GSK leads through Bexsero, Menveo and Penmenvy, followed by Sanofi and Pfizer. Serum Institute of India has an important position in African public-health procurement through MenAfriVac and MenFive, although its revenue share is lower than its dose share. China has a broader manufacturing base spanning MenA, MenAC and MenACWY products. North America is the largest value market, followed by Europe, while China and Africa account for a disproportionately large share of global dose volume.
During 2026?2032, demand is expected to move further from plain polysaccharide vaccines toward conjugate and broader multivalent products. MenFive adoption should expand protection against serogroups A, C, W, Y and X in the African meningitis belt. MenABCWY products may simplify immunization for adolescents and high-risk populations currently requiring separate MenACWY and MenB vaccinations. However, the pentavalent category will remain concentrated in a small number of manufacturers because of its complex antigen composition, clinical requirements and multi-component presentation. Regulatory authorities will continue to emphasize lot consistency, age-specific effectiveness, post-marketing surveillance and long-term supply reliability. Public tenders will maintain pricing pressure, while wider reimbursement of MenB and pentavalent vaccines should support gradual ASP growth. Key bottlenecks include long biological production and release cycles, limited antigen and carrier-protein capacity, sterile fill-finish constraints, cold-chain requirements and irregular government procurement. Changes in circulating serogroups may also require revisions to national schedules and stockpile composition.
LP Information, Inc. (LPI) ' newest research report, the ?Meningococcal Vaccine Industry Forecast? looks at past sales and reviews total world Meningococcal Vaccine sales in 2025, providing a comprehensive analysis by region and market sector of projected Meningococcal Vaccine sales for 2026 through 2032. With Meningococcal Vaccine sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Meningococcal Vaccine industry.
This Insight Report provides a comprehensive analysis of the global Meningococcal Vaccine landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Meningococcal Vaccine portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms? unique position in an accelerating global Meningococcal Vaccine market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Meningococcal Vaccine and breaks down the forecast by Vaccine Platform, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Meningococcal Vaccine.
This report presents a comprehensive overview, market shares, and growth opportunities of Meningococcal Vaccine market by product type, application, key manufacturers and key regions and countries.
Segmentation by Vaccine Platform:
What is the 10-year outlook for the global Meningococcal Vaccine market?
What factors are driving Meningococcal Vaccine market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Meningococcal Vaccine market opportunities vary by end market size?
How does Meningococcal Vaccine break out by Vaccine Platform, by Application?
Meningococcal vaccines are preventive biological products designed to generate active immunity against invasive disease caused by Neisseria meningitidis. They are used in routine childhood and adolescent immunization, preventive campaigns, outbreak response, travel vaccination and the protection of medically or occupationally exposed populations. Current marketed serogroup configurations include monovalent MenA, MenB and MenC vaccines; bivalent MenAC and MenBC vaccines; trivalent MenACW vaccines; quadrivalent MenACWY vaccines; and pentavalent MenABCWY and MenACWYX vaccines. MenABCWY is an emerging commercial segment represented by Pfizer?s Penbraya and GSK?s Penmenvy, while MenACWYX is represented by Serum Institute of India?s MenFive. Commercial technology platforms comprise plain polysaccharide vaccines, conjugate vaccines, recombinant protein vaccines and multi-platform products combining conjugate, recombinant protein or outer-membrane-vesicle components.
Upstream supply depends on qualified meningococcal strains, capsular polysaccharides, recombinant antigens, outer-membrane-vesicle antigens, carrier proteins, stabilizers, sterile containers and validated cold-chain packaging. Manufacturing remains concentrated because biological consistency, aseptic processing, analytical comparability, regulatory approval and lot-release testing must be maintained over long production cycles. Downstream purchasers include ministries of health, national immunization programs, international procurement organizations, hospitals, vaccination clinics, pharmacies, travel-health centers, military organizations, universities and occupational-health providers. Public demand is commonly supplied through annual tenders, multi-year framework agreements, stockpile contracts and emergency procurement, while commercial vaccines are distributed through direct supply agreements and specialist health-care channels. Industry gross margin is estimated at approximately 68%, supported by premium-priced conjugate, MenB and pentavalent products but moderated by lower-price public-health procurement.
In the current market, global production of meningococcal vaccines is around 197 million doses, with an average selling price of about 21.00 USD per dose on an EXW basis. Value is more concentrated than physical volume because commercial MenB, MenACWY and MenABCWY vaccines command substantially higher prices than polysaccharide and public-procurement products used extensively in China and the African meningitis belt. The top five suppliers control approximately 84% of global revenue. GSK leads through Bexsero, Menveo and Penmenvy, followed by Sanofi and Pfizer. Serum Institute of India has an important position in African public-health procurement through MenAfriVac and MenFive, although its revenue share is lower than its dose share. China has a broader manufacturing base spanning MenA, MenAC and MenACWY products. North America is the largest value market, followed by Europe, while China and Africa account for a disproportionately large share of global dose volume.
During 2026?2032, demand is expected to move further from plain polysaccharide vaccines toward conjugate and broader multivalent products. MenFive adoption should expand protection against serogroups A, C, W, Y and X in the African meningitis belt. MenABCWY products may simplify immunization for adolescents and high-risk populations currently requiring separate MenACWY and MenB vaccinations. However, the pentavalent category will remain concentrated in a small number of manufacturers because of its complex antigen composition, clinical requirements and multi-component presentation. Regulatory authorities will continue to emphasize lot consistency, age-specific effectiveness, post-marketing surveillance and long-term supply reliability. Public tenders will maintain pricing pressure, while wider reimbursement of MenB and pentavalent vaccines should support gradual ASP growth. Key bottlenecks include long biological production and release cycles, limited antigen and carrier-protein capacity, sterile fill-finish constraints, cold-chain requirements and irregular government procurement. Changes in circulating serogroups may also require revisions to national schedules and stockpile composition.
LP Information, Inc. (LPI) ' newest research report, the ?Meningococcal Vaccine Industry Forecast? looks at past sales and reviews total world Meningococcal Vaccine sales in 2025, providing a comprehensive analysis by region and market sector of projected Meningococcal Vaccine sales for 2026 through 2032. With Meningococcal Vaccine sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Meningococcal Vaccine industry.
This Insight Report provides a comprehensive analysis of the global Meningococcal Vaccine landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Meningococcal Vaccine portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms? unique position in an accelerating global Meningococcal Vaccine market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Meningococcal Vaccine and breaks down the forecast by Vaccine Platform, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Meningococcal Vaccine.
This report presents a comprehensive overview, market shares, and growth opportunities of Meningococcal Vaccine market by product type, application, key manufacturers and key regions and countries.
Segmentation by Vaccine Platform:
- Plain Polysaccharide Vaccines
- Conjugate Vaccines
- Recombinant Protein Vaccines
- Multi-Platform Vaccines
- MenA Vaccines
- MenB Vaccines
- MenC Vaccines
- MenAC Vaccines
- MenBC Vaccines
- MenACW Vaccines
- MenACWY Vaccines
- MenABCWY Vaccines
- MenACWYX Vaccines
- Single-Dose Liquid
- Multi-Dose Liquid
- Single-Dose Lyophilized
- Multi-Dose Lyophilized
- Multi-Component Kit
- Routine Pediatric Immunization
- Routine Adolescent Immunization
- Preventive Mass Campaigns
- Outbreak Response
- High-Risk Clinical Immunization
- Travel Immunization
- Institutional Immunization
- Occupational Immunization
- Catch-Up Immunization
- Other Immunization
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- GSK
- Sanofi
- Pfizer
- Serum Institute of India
- CanSino Biologics
- Yuxi Walvax Biotechnology
- Beijing Zhifei Lvzhu Biopharmaceutical
- China National Biotec Group
- Funda??o Oswaldo Cruz
- Funda??o Ezequiel Dias
- Instituto Finlay de Vacunas
- PT Bio Farma
- Hualan Biological Bacterin
- Chengdu Olymvax Biopharmaceuticals
- Royal Wuxi Bio-Pharmaceutical
- AIM Persistence Biopharmaceutical
- NPO Microgen
- Incepta Vaccine
What is the 10-year outlook for the global Meningococcal Vaccine market?
What factors are driving Meningococcal Vaccine market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Meningococcal Vaccine market opportunities vary by end market size?
How does Meningococcal Vaccine break out by Vaccine Platform, by Application?
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Meningococcal Vaccine Annual Sales 2021-2032
2.1.2 World Current & Future Analysis for Meningococcal Vaccine by Geographic Region, 2021, 2025 & 2032
2.1.3 World Current & Future Analysis for Meningococcal Vaccine by Country/Region, 2021, 2025 & 2032
2.2 Meningococcal Vaccine Segment by Vaccine Platform
2.2.1 Plain Polysaccharide Vaccines
2.2.2 Conjugate Vaccines
2.2.3 Recombinant Protein Vaccines
2.2.4 Multi-Platform Vaccines
2.2.5 Meningococcal Vaccine Sales by Vaccine Platform
2.2.5.1 Global Meningococcal Vaccine Sales Market Share by Vaccine Platform (2021-2026)
2.2.5.2 Global Meningococcal Vaccine Revenue and Market Share by Vaccine Platform (2021-2026)
2.2.5.3 Global Meningococcal Vaccine Sale Price by Vaccine Platform (2021-2026)
2.3 Meningococcal Vaccine Segment by Serogroup Coverage
2.3.1 MenA Vaccines
2.3.2 MenB Vaccines
2.3.3 MenC Vaccines
2.3.4 MenAC Vaccines
2.3.5 MenBC Vaccines
2.3.6 MenACW Vaccines
2.3.7 MenACWY Vaccines
2.3.8 MenABCWY Vaccines
2.3.9 MenACWYX Vaccines
2.3.10 Meningococcal Vaccine Sales by Serogroup Coverage
2.3.10.1 Global Meningococcal Vaccine Sales Market Share by Serogroup Coverage (2021-2026)
2.3.10.2 Global Meningococcal Vaccine Revenue and Market Share by Serogroup Coverage (2021-2026)
2.3.10.3 Global Meningococcal Vaccine Sale Price by Serogroup Coverage (2021-2026)
2.4 Meningococcal Vaccine Segment by Presentation
2.4.1 Single-Dose Liquid
2.4.2 Multi-Dose Liquid
2.4.3 Single-Dose Lyophilized
2.4.4 Multi-Dose Lyophilized
2.4.5 Multi-Component Kit
2.4.6 Meningococcal Vaccine Sales by Presentation
2.4.6.1 Global Meningococcal Vaccine Sales Market Share by Presentation (2021-2026)
2.4.6.2 Global Meningococcal Vaccine Revenue and Market Share by Presentation (2021-2026)
2.4.6.3 Global Meningococcal Vaccine Sale Price by Presentation (2021-2026)
2.5 Meningococcal Vaccine Segment by Application
2.5.1 Routine Pediatric Immunization
2.5.2 Routine Adolescent Immunization
2.5.3 Preventive Mass Campaigns
2.5.4 Outbreak Response
2.5.5 High-Risk Clinical Immunization
2.5.6 Travel Immunization
2.5.7 Institutional Immunization
2.5.8 Occupational Immunization
2.5.9 Catch-Up Immunization
2.5.10 Meningococcal Vaccine Sales by Application
2.5.10.1 Global Meningococcal Vaccine Sale Market Share by Application (2021-2026)
2.5.10.2 Global Meningococcal Vaccine Revenue and Market Share by Application (2021-2026)
2.5.10.3 Global Meningococcal Vaccine Sale Price by Application (2021-2026)
3 GLOBAL BY COMPANY
3.1 Global Meningococcal Vaccine Breakdown Data by Company
3.1.1 Global Meningococcal Vaccine Annual Sales by Company (2021-2026)
3.1.2 Global Meningococcal Vaccine Sales Market Share by Company (2021-2026)
3.2 Global Meningococcal Vaccine Annual Revenue by Company (2021-2026)
3.2.1 Global Meningococcal Vaccine Revenue by Company (2021-2026)
3.2.2 Global Meningococcal Vaccine Revenue Market Share by Company (2021-2026)
3.3 Global Meningococcal Vaccine Sale Price by Company
3.4 Key Manufacturers Meningococcal Vaccine Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Meningococcal Vaccine Product Location Distribution
3.4.2 Players Meningococcal Vaccine Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR MENINGOCOCCAL VACCINE BY GEOGRAPHIC REGION
4.1 World Historic Meningococcal Vaccine Market Size by Geographic Region (2021-2026)
4.1.1 Global Meningococcal Vaccine Annual Sales by Geographic Region (2021-2026)
4.1.2 Global Meningococcal Vaccine Annual Revenue by Geographic Region (2021-2026)
4.2 World Historic Meningococcal Vaccine Market Size by Country/Region (2021-2026)
4.2.1 Global Meningococcal Vaccine Annual Sales by Country/Region (2021-2026)
4.2.2 Global Meningococcal Vaccine Annual Revenue by Country/Region (2021-2026)
4.3 Americas Meningococcal Vaccine Sales Growth
4.4 APAC Meningococcal Vaccine Sales Growth
4.5 Europe Meningococcal Vaccine Sales Growth
4.6 Middle East & Africa Meningococcal Vaccine Sales Growth
5 AMERICAS
5.1 Americas Meningococcal Vaccine Sales by Country
5.1.1 Americas Meningococcal Vaccine Sales by Country (2021-2026)
5.1.2 Americas Meningococcal Vaccine Revenue by Country (2021-2026)
5.2 Americas Meningococcal Vaccine Sales by Vaccine Platform (2021-2026)
5.3 Americas Meningococcal Vaccine Sales by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Meningococcal Vaccine Sales by Region
6.1.1 APAC Meningococcal Vaccine Sales by Region (2021-2026)
6.1.2 APAC Meningococcal Vaccine Revenue by Region (2021-2026)
6.2 APAC Meningococcal Vaccine Sales by Vaccine Platform (2021-2026)
6.3 APAC Meningococcal Vaccine Sales by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Meningococcal Vaccine by Country
7.1.1 Europe Meningococcal Vaccine Sales by Country (2021-2026)
7.1.2 Europe Meningococcal Vaccine Revenue by Country (2021-2026)
7.2 Europe Meningococcal Vaccine Sales by Vaccine Platform (2021-2026)
7.3 Europe Meningococcal Vaccine Sales by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Meningococcal Vaccine by Country
8.1.1 Middle East & Africa Meningococcal Vaccine Sales by Country (2021-2026)
8.1.2 Middle East & Africa Meningococcal Vaccine Revenue by Country (2021-2026)
8.2 Middle East & Africa Meningococcal Vaccine Sales by Vaccine Platform (2021-2026)
8.3 Middle East & Africa Meningococcal Vaccine Sales by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Meningococcal Vaccine
10.3 Manufacturing Process Analysis of Meningococcal Vaccine
10.4 Industry Chain Structure of Meningococcal Vaccine
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Meningococcal Vaccine Distributors
11.3 Meningococcal Vaccine Customer
12 WORLD FORECAST REVIEW FOR MENINGOCOCCAL VACCINE BY GEOGRAPHIC REGION
12.1 Global Meningococcal Vaccine Market Size Forecast by Region
12.1.1 Global Meningococcal Vaccine Forecast by Region (2027-2032)
12.1.2 Global Meningococcal Vaccine Annual Revenue Forecast by Region (2027-2032)
12.2 Americas Forecast by Country (2027-2032)
12.3 APAC Forecast by Region (2027-2032)
12.4 Europe Forecast by Country (2027-2032)
12.5 Middle East & Africa Forecast by Country (2027-2032)
12.6 Global Meningococcal Vaccine Forecast by Vaccine Platform (2027-2032)
12.7 Global Meningococcal Vaccine Forecast by Application (2027-2032)
13 KEY PLAYERS ANALYSIS
13.1 GSK
13.1.1 GSK Company Information
13.1.2 GSK Meningococcal Vaccine Product Portfolios and Specifications
13.1.3 GSK Meningococcal Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.1.4 GSK Main Business Overview
13.1.5 GSK Latest Developments
13.2 Sanofi
13.2.1 Sanofi Company Information
13.2.2 Sanofi Meningococcal Vaccine Product Portfolios and Specifications
13.2.3 Sanofi Meningococcal Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.2.4 Sanofi Main Business Overview
13.2.5 Sanofi Latest Developments
13.3 Pfizer
13.3.1 Pfizer Company Information
13.3.2 Pfizer Meningococcal Vaccine Product Portfolios and Specifications
13.3.3 Pfizer Meningococcal Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.3.4 Pfizer Main Business Overview
13.3.5 Pfizer Latest Developments
13.4 Serum Institute of India
13.4.1 Serum Institute of India Company Information
13.4.2 Serum Institute of India Meningococcal Vaccine Product Portfolios and Specifications
13.4.3 Serum Institute of India Meningococcal Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.4.4 Serum Institute of India Main Business Overview
13.4.5 Serum Institute of India Latest Developments
13.5 CanSino Biologics
13.5.1 CanSino Biologics Company Information
13.5.2 CanSino Biologics Meningococcal Vaccine Product Portfolios and Specifications
13.5.3 CanSino Biologics Meningococcal Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.5.4 CanSino Biologics Main Business Overview
13.5.5 CanSino Biologics Latest Developments
13.6 Yuxi Walvax Biotechnology
13.6.1 Yuxi Walvax Biotechnology Company Information
13.6.2 Yuxi Walvax Biotechnology Meningococcal Vaccine Product Portfolios and Specifications
13.6.3 Yuxi Walvax Biotechnology Meningococcal Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.6.4 Yuxi Walvax Biotechnology Main Business Overview
13.6.5 Yuxi Walvax Biotechnology Latest Developments
13.7 Beijing Zhifei Lvzhu Biopharmaceutical
13.7.1 Beijing Zhifei Lvzhu Biopharmaceutical Company Information
13.7.2 Beijing Zhifei Lvzhu Biopharmaceutical Meningococcal Vaccine Product Portfolios and Specifications
13.7.3 Beijing Zhifei Lvzhu Biopharmaceutical Meningococcal Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.7.4 Beijing Zhifei Lvzhu Biopharmaceutical Main Business Overview
13.7.5 Beijing Zhifei Lvzhu Biopharmaceutical Latest Developments
13.8 China National Biotec Group
13.8.1 China National Biotec Group Company Information
13.8.2 China National Biotec Group Meningococcal Vaccine Product Portfolios and Specifications
13.8.3 China National Biotec Group Meningococcal Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.8.4 China National Biotec Group Main Business Overview
13.8.5 China National Biotec Group Latest Developments
13.9 Funda??o Oswaldo Cruz
13.9.1 Funda??o Oswaldo Cruz Company Information
13.9.2 Funda??o Oswaldo Cruz Meningococcal Vaccine Product Portfolios and Specifications
13.9.3 Funda??o Oswaldo Cruz Meningococcal Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.9.4 Funda??o Oswaldo Cruz Main Business Overview
13.9.5 Funda??o Oswaldo Cruz Latest Developments
13.10 Funda??o Ezequiel Dias
13.10.1 Funda??o Ezequiel Dias Company Information
13.10.2 Funda??o Ezequiel Dias Meningococcal Vaccine Product Portfolios and Specifications
13.10.3 Funda??o Ezequiel Dias Meningococcal Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.10.4 Funda??o Ezequiel Dias Main Business Overview
13.10.5 Funda??o Ezequiel Dias Latest Developments
13.11 Instituto Finlay de Vacunas
13.11.1 Instituto Finlay de Vacunas Company Information
13.11.2 Instituto Finlay de Vacunas Meningococcal Vaccine Product Portfolios and Specifications
13.11.3 Instituto Finlay de Vacunas Meningococcal Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.11.4 Instituto Finlay de Vacunas Main Business Overview
13.11.5 Instituto Finlay de Vacunas Latest Developments
13.12 PT Bio Farma
13.12.1 PT Bio Farma Company Information
13.12.2 PT Bio Farma Meningococcal Vaccine Product Portfolios and Specifications
13.12.3 PT Bio Farma Meningococcal Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.12.4 PT Bio Farma Main Business Overview
13.12.5 PT Bio Farma Latest Developments
13.13 Hualan Biological Bacterin
13.13.1 Hualan Biological Bacterin Company Information
13.13.2 Hualan Biological Bacterin Meningococcal Vaccine Product Portfolios and Specifications
13.13.3 Hualan Biological Bacterin Meningococcal Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.13.4 Hualan Biological Bacterin Main Business Overview
13.13.5 Hualan Biological Bacterin Latest Developments
13.14 Chengdu Olymvax Biopharmaceuticals
13.14.1 Chengdu Olymvax Biopharmaceuticals Company Information
13.14.2 Chengdu Olymvax Biopharmaceuticals Meningococcal Vaccine Product Portfolios and Specifications
13.14.3 Chengdu Olymvax Biopharmaceuticals Meningococcal Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.14.4 Chengdu Olymvax Biopharmaceuticals Main Business Overview
13.14.5 Chengdu Olymvax Biopharmaceuticals Latest Developments
13.15 Royal Wuxi Bio-Pharmaceutical
13.15.1 Royal Wuxi Bio-Pharmaceutical Company Information
13.15.2 Royal Wuxi Bio-Pharmaceutical Meningococcal Vaccine Product Portfolios and Specifications
13.15.3 Royal Wuxi Bio-Pharmaceutical Meningococcal Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.15.4 Royal Wuxi Bio-Pharmaceutical Main Business Overview
13.15.5 Royal Wuxi Bio-Pharmaceutical Latest Developments
13.16 AIM Persistence Biopharmaceutical
13.16.1 AIM Persistence Biopharmaceutical Company Information
13.16.2 AIM Persistence Biopharmaceutical Meningococcal Vaccine Product Portfolios and Specifications
13.16.3 AIM Persistence Biopharmaceutical Meningococcal Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.16.4 AIM Persistence Biopharmaceutical Main Business Overview
13.16.5 AIM Persistence Biopharmaceutical Latest Developments
13.17 NPO Microgen
13.17.1 NPO Microgen Company Information
13.17.2 NPO Microgen Meningococcal Vaccine Product Portfolios and Specifications
13.17.3 NPO Microgen Meningococcal Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.17.4 NPO Microgen Main Business Overview
13.17.5 NPO Microgen Latest Developments
13.18 Incepta Vaccine
13.18.1 Incepta Vaccine Company Information
13.18.2 Incepta Vaccine Meningococcal Vaccine Product Portfolios and Specifications
13.18.3 Incepta Vaccine Meningococcal Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.18.4 Incepta Vaccine Main Business Overview
13.18.5 Incepta Vaccine Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Meningococcal Vaccine Annual Sales 2021-2032
2.1.2 World Current & Future Analysis for Meningococcal Vaccine by Geographic Region, 2021, 2025 & 2032
2.1.3 World Current & Future Analysis for Meningococcal Vaccine by Country/Region, 2021, 2025 & 2032
2.2 Meningococcal Vaccine Segment by Vaccine Platform
2.2.1 Plain Polysaccharide Vaccines
2.2.2 Conjugate Vaccines
2.2.3 Recombinant Protein Vaccines
2.2.4 Multi-Platform Vaccines
2.2.5 Meningococcal Vaccine Sales by Vaccine Platform
2.2.5.1 Global Meningococcal Vaccine Sales Market Share by Vaccine Platform (2021-2026)
2.2.5.2 Global Meningococcal Vaccine Revenue and Market Share by Vaccine Platform (2021-2026)
2.2.5.3 Global Meningococcal Vaccine Sale Price by Vaccine Platform (2021-2026)
2.3 Meningococcal Vaccine Segment by Serogroup Coverage
2.3.1 MenA Vaccines
2.3.2 MenB Vaccines
2.3.3 MenC Vaccines
2.3.4 MenAC Vaccines
2.3.5 MenBC Vaccines
2.3.6 MenACW Vaccines
2.3.7 MenACWY Vaccines
2.3.8 MenABCWY Vaccines
2.3.9 MenACWYX Vaccines
2.3.10 Meningococcal Vaccine Sales by Serogroup Coverage
2.3.10.1 Global Meningococcal Vaccine Sales Market Share by Serogroup Coverage (2021-2026)
2.3.10.2 Global Meningococcal Vaccine Revenue and Market Share by Serogroup Coverage (2021-2026)
2.3.10.3 Global Meningococcal Vaccine Sale Price by Serogroup Coverage (2021-2026)
2.4 Meningococcal Vaccine Segment by Presentation
2.4.1 Single-Dose Liquid
2.4.2 Multi-Dose Liquid
2.4.3 Single-Dose Lyophilized
2.4.4 Multi-Dose Lyophilized
2.4.5 Multi-Component Kit
2.4.6 Meningococcal Vaccine Sales by Presentation
2.4.6.1 Global Meningococcal Vaccine Sales Market Share by Presentation (2021-2026)
2.4.6.2 Global Meningococcal Vaccine Revenue and Market Share by Presentation (2021-2026)
2.4.6.3 Global Meningococcal Vaccine Sale Price by Presentation (2021-2026)
2.5 Meningococcal Vaccine Segment by Application
2.5.1 Routine Pediatric Immunization
2.5.2 Routine Adolescent Immunization
2.5.3 Preventive Mass Campaigns
2.5.4 Outbreak Response
2.5.5 High-Risk Clinical Immunization
2.5.6 Travel Immunization
2.5.7 Institutional Immunization
2.5.8 Occupational Immunization
2.5.9 Catch-Up Immunization
2.5.10 Meningococcal Vaccine Sales by Application
2.5.10.1 Global Meningococcal Vaccine Sale Market Share by Application (2021-2026)
2.5.10.2 Global Meningococcal Vaccine Revenue and Market Share by Application (2021-2026)
2.5.10.3 Global Meningococcal Vaccine Sale Price by Application (2021-2026)
3 GLOBAL BY COMPANY
3.1 Global Meningococcal Vaccine Breakdown Data by Company
3.1.1 Global Meningococcal Vaccine Annual Sales by Company (2021-2026)
3.1.2 Global Meningococcal Vaccine Sales Market Share by Company (2021-2026)
3.2 Global Meningococcal Vaccine Annual Revenue by Company (2021-2026)
3.2.1 Global Meningococcal Vaccine Revenue by Company (2021-2026)
3.2.2 Global Meningococcal Vaccine Revenue Market Share by Company (2021-2026)
3.3 Global Meningococcal Vaccine Sale Price by Company
3.4 Key Manufacturers Meningococcal Vaccine Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Meningococcal Vaccine Product Location Distribution
3.4.2 Players Meningococcal Vaccine Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR MENINGOCOCCAL VACCINE BY GEOGRAPHIC REGION
4.1 World Historic Meningococcal Vaccine Market Size by Geographic Region (2021-2026)
4.1.1 Global Meningococcal Vaccine Annual Sales by Geographic Region (2021-2026)
4.1.2 Global Meningococcal Vaccine Annual Revenue by Geographic Region (2021-2026)
4.2 World Historic Meningococcal Vaccine Market Size by Country/Region (2021-2026)
4.2.1 Global Meningococcal Vaccine Annual Sales by Country/Region (2021-2026)
4.2.2 Global Meningococcal Vaccine Annual Revenue by Country/Region (2021-2026)
4.3 Americas Meningococcal Vaccine Sales Growth
4.4 APAC Meningococcal Vaccine Sales Growth
4.5 Europe Meningococcal Vaccine Sales Growth
4.6 Middle East & Africa Meningococcal Vaccine Sales Growth
5 AMERICAS
5.1 Americas Meningococcal Vaccine Sales by Country
5.1.1 Americas Meningococcal Vaccine Sales by Country (2021-2026)
5.1.2 Americas Meningococcal Vaccine Revenue by Country (2021-2026)
5.2 Americas Meningococcal Vaccine Sales by Vaccine Platform (2021-2026)
5.3 Americas Meningococcal Vaccine Sales by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Meningococcal Vaccine Sales by Region
6.1.1 APAC Meningococcal Vaccine Sales by Region (2021-2026)
6.1.2 APAC Meningococcal Vaccine Revenue by Region (2021-2026)
6.2 APAC Meningococcal Vaccine Sales by Vaccine Platform (2021-2026)
6.3 APAC Meningococcal Vaccine Sales by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Meningococcal Vaccine by Country
7.1.1 Europe Meningococcal Vaccine Sales by Country (2021-2026)
7.1.2 Europe Meningococcal Vaccine Revenue by Country (2021-2026)
7.2 Europe Meningococcal Vaccine Sales by Vaccine Platform (2021-2026)
7.3 Europe Meningococcal Vaccine Sales by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Meningococcal Vaccine by Country
8.1.1 Middle East & Africa Meningococcal Vaccine Sales by Country (2021-2026)
8.1.2 Middle East & Africa Meningococcal Vaccine Revenue by Country (2021-2026)
8.2 Middle East & Africa Meningococcal Vaccine Sales by Vaccine Platform (2021-2026)
8.3 Middle East & Africa Meningococcal Vaccine Sales by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Meningococcal Vaccine
10.3 Manufacturing Process Analysis of Meningococcal Vaccine
10.4 Industry Chain Structure of Meningococcal Vaccine
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Meningococcal Vaccine Distributors
11.3 Meningococcal Vaccine Customer
12 WORLD FORECAST REVIEW FOR MENINGOCOCCAL VACCINE BY GEOGRAPHIC REGION
12.1 Global Meningococcal Vaccine Market Size Forecast by Region
12.1.1 Global Meningococcal Vaccine Forecast by Region (2027-2032)
12.1.2 Global Meningococcal Vaccine Annual Revenue Forecast by Region (2027-2032)
12.2 Americas Forecast by Country (2027-2032)
12.3 APAC Forecast by Region (2027-2032)
12.4 Europe Forecast by Country (2027-2032)
12.5 Middle East & Africa Forecast by Country (2027-2032)
12.6 Global Meningococcal Vaccine Forecast by Vaccine Platform (2027-2032)
12.7 Global Meningococcal Vaccine Forecast by Application (2027-2032)
13 KEY PLAYERS ANALYSIS
13.1 GSK
13.1.1 GSK Company Information
13.1.2 GSK Meningococcal Vaccine Product Portfolios and Specifications
13.1.3 GSK Meningococcal Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.1.4 GSK Main Business Overview
13.1.5 GSK Latest Developments
13.2 Sanofi
13.2.1 Sanofi Company Information
13.2.2 Sanofi Meningococcal Vaccine Product Portfolios and Specifications
13.2.3 Sanofi Meningococcal Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.2.4 Sanofi Main Business Overview
13.2.5 Sanofi Latest Developments
13.3 Pfizer
13.3.1 Pfizer Company Information
13.3.2 Pfizer Meningococcal Vaccine Product Portfolios and Specifications
13.3.3 Pfizer Meningococcal Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.3.4 Pfizer Main Business Overview
13.3.5 Pfizer Latest Developments
13.4 Serum Institute of India
13.4.1 Serum Institute of India Company Information
13.4.2 Serum Institute of India Meningococcal Vaccine Product Portfolios and Specifications
13.4.3 Serum Institute of India Meningococcal Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.4.4 Serum Institute of India Main Business Overview
13.4.5 Serum Institute of India Latest Developments
13.5 CanSino Biologics
13.5.1 CanSino Biologics Company Information
13.5.2 CanSino Biologics Meningococcal Vaccine Product Portfolios and Specifications
13.5.3 CanSino Biologics Meningococcal Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.5.4 CanSino Biologics Main Business Overview
13.5.5 CanSino Biologics Latest Developments
13.6 Yuxi Walvax Biotechnology
13.6.1 Yuxi Walvax Biotechnology Company Information
13.6.2 Yuxi Walvax Biotechnology Meningococcal Vaccine Product Portfolios and Specifications
13.6.3 Yuxi Walvax Biotechnology Meningococcal Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.6.4 Yuxi Walvax Biotechnology Main Business Overview
13.6.5 Yuxi Walvax Biotechnology Latest Developments
13.7 Beijing Zhifei Lvzhu Biopharmaceutical
13.7.1 Beijing Zhifei Lvzhu Biopharmaceutical Company Information
13.7.2 Beijing Zhifei Lvzhu Biopharmaceutical Meningococcal Vaccine Product Portfolios and Specifications
13.7.3 Beijing Zhifei Lvzhu Biopharmaceutical Meningococcal Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.7.4 Beijing Zhifei Lvzhu Biopharmaceutical Main Business Overview
13.7.5 Beijing Zhifei Lvzhu Biopharmaceutical Latest Developments
13.8 China National Biotec Group
13.8.1 China National Biotec Group Company Information
13.8.2 China National Biotec Group Meningococcal Vaccine Product Portfolios and Specifications
13.8.3 China National Biotec Group Meningococcal Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.8.4 China National Biotec Group Main Business Overview
13.8.5 China National Biotec Group Latest Developments
13.9 Funda??o Oswaldo Cruz
13.9.1 Funda??o Oswaldo Cruz Company Information
13.9.2 Funda??o Oswaldo Cruz Meningococcal Vaccine Product Portfolios and Specifications
13.9.3 Funda??o Oswaldo Cruz Meningococcal Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.9.4 Funda??o Oswaldo Cruz Main Business Overview
13.9.5 Funda??o Oswaldo Cruz Latest Developments
13.10 Funda??o Ezequiel Dias
13.10.1 Funda??o Ezequiel Dias Company Information
13.10.2 Funda??o Ezequiel Dias Meningococcal Vaccine Product Portfolios and Specifications
13.10.3 Funda??o Ezequiel Dias Meningococcal Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.10.4 Funda??o Ezequiel Dias Main Business Overview
13.10.5 Funda??o Ezequiel Dias Latest Developments
13.11 Instituto Finlay de Vacunas
13.11.1 Instituto Finlay de Vacunas Company Information
13.11.2 Instituto Finlay de Vacunas Meningococcal Vaccine Product Portfolios and Specifications
13.11.3 Instituto Finlay de Vacunas Meningococcal Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.11.4 Instituto Finlay de Vacunas Main Business Overview
13.11.5 Instituto Finlay de Vacunas Latest Developments
13.12 PT Bio Farma
13.12.1 PT Bio Farma Company Information
13.12.2 PT Bio Farma Meningococcal Vaccine Product Portfolios and Specifications
13.12.3 PT Bio Farma Meningococcal Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.12.4 PT Bio Farma Main Business Overview
13.12.5 PT Bio Farma Latest Developments
13.13 Hualan Biological Bacterin
13.13.1 Hualan Biological Bacterin Company Information
13.13.2 Hualan Biological Bacterin Meningococcal Vaccine Product Portfolios and Specifications
13.13.3 Hualan Biological Bacterin Meningococcal Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.13.4 Hualan Biological Bacterin Main Business Overview
13.13.5 Hualan Biological Bacterin Latest Developments
13.14 Chengdu Olymvax Biopharmaceuticals
13.14.1 Chengdu Olymvax Biopharmaceuticals Company Information
13.14.2 Chengdu Olymvax Biopharmaceuticals Meningococcal Vaccine Product Portfolios and Specifications
13.14.3 Chengdu Olymvax Biopharmaceuticals Meningococcal Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.14.4 Chengdu Olymvax Biopharmaceuticals Main Business Overview
13.14.5 Chengdu Olymvax Biopharmaceuticals Latest Developments
13.15 Royal Wuxi Bio-Pharmaceutical
13.15.1 Royal Wuxi Bio-Pharmaceutical Company Information
13.15.2 Royal Wuxi Bio-Pharmaceutical Meningococcal Vaccine Product Portfolios and Specifications
13.15.3 Royal Wuxi Bio-Pharmaceutical Meningococcal Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.15.4 Royal Wuxi Bio-Pharmaceutical Main Business Overview
13.15.5 Royal Wuxi Bio-Pharmaceutical Latest Developments
13.16 AIM Persistence Biopharmaceutical
13.16.1 AIM Persistence Biopharmaceutical Company Information
13.16.2 AIM Persistence Biopharmaceutical Meningococcal Vaccine Product Portfolios and Specifications
13.16.3 AIM Persistence Biopharmaceutical Meningococcal Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.16.4 AIM Persistence Biopharmaceutical Main Business Overview
13.16.5 AIM Persistence Biopharmaceutical Latest Developments
13.17 NPO Microgen
13.17.1 NPO Microgen Company Information
13.17.2 NPO Microgen Meningococcal Vaccine Product Portfolios and Specifications
13.17.3 NPO Microgen Meningococcal Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.17.4 NPO Microgen Main Business Overview
13.17.5 NPO Microgen Latest Developments
13.18 Incepta Vaccine
13.18.1 Incepta Vaccine Company Information
13.18.2 Incepta Vaccine Meningococcal Vaccine Product Portfolios and Specifications
13.18.3 Incepta Vaccine Meningococcal Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.18.4 Incepta Vaccine Main Business Overview
13.18.5 Incepta Vaccine Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES
Table 1. Meningococcal Vaccine Annual Sales CAGR by Geographic Region (2021, 2025 & 2032) & ($ millions)
Table 2. Meningococcal Vaccine Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of Plain Polysaccharide Vaccines
Table 4. Major Players of Conjugate Vaccines
Table 5. Major Players of Recombinant Protein Vaccines
Table 6. Major Players of Multi-Platform Vaccines
Table 7. Global Meningococcal Vaccine Sales by Vaccine Platform (2021-2026) & (million Dose)
Table 8. Global Meningococcal Vaccine Sales Market Share by Vaccine Platform (2021-2026)
Table 9. Global Meningococcal Vaccine Revenue by Vaccine Platform (2021-2026) & ($ million)
Table 10. Global Meningococcal Vaccine Revenue Market Share by Vaccine Platform (2021-2026)
Table 11. Global Meningococcal Vaccine Sale Price by Vaccine Platform (2021-2026) & (US$/Dose)
Table 12. Major Players of MenA Vaccines
Table 13. Major Players of MenB Vaccines
Table 14. Major Players of MenC Vaccines
Table 15. Major Players of MenAC Vaccines
Table 16. Major Players of MenBC Vaccines
Table 17. Major Players of MenACW Vaccines
Table 18. Major Players of MenACWY Vaccines
Table 19. Major Players of MenABCWY Vaccines
Table 20. Major Players of MenACWYX Vaccines
Table 21. Global Meningococcal Vaccine Sales by Serogroup Coverage (2021-2026) & (million Dose)
Table 22. Global Meningococcal Vaccine Sales Market Share by Serogroup Coverage (2021-2026)
Table 23. Global Meningococcal Vaccine Revenue by Serogroup Coverage (2021-2026) & ($ million)
Table 24. Global Meningococcal Vaccine Revenue Market Share by Serogroup Coverage (2021-2026)
Table 25. Global Meningococcal Vaccine Sale Price by Serogroup Coverage (2021-2026) & (US$/Dose)
Table 26. Major Players of Single-Dose Liquid
Table 27. Major Players of Multi-Dose Liquid
Table 28. Major Players of Single-Dose Lyophilized
Table 29. Major Players of Multi-Dose Lyophilized
Table 30. Major Players of Multi-Component Kit
Table 31. Global Meningococcal Vaccine Sales by Presentation (2021-2026) & (million Dose)
Table 32. Global Meningococcal Vaccine Sales Market Share by Presentation (2021-2026)
Table 33. Global Meningococcal Vaccine Revenue by Presentation (2021-2026) & ($ million)
Table 34. Global Meningococcal Vaccine Revenue Market Share by Presentation (2021-2026)
Table 35. Global Meningococcal Vaccine Sale Price by Presentation (2021-2026) & (US$/Dose)
Table 36. Global Meningococcal Vaccine Sale by Application (2021-2026) & (million Dose)
Table 37. Global Meningococcal Vaccine Sale Market Share by Application (2021-2026)
Table 38. Global Meningococcal Vaccine Revenue by Application (2021-2026) & ($ million)
Table 39. Global Meningococcal Vaccine Revenue Market Share by Application (2021-2026)
Table 40. Global Meningococcal Vaccine Sale Price by Application (2021-2026) & (US$/Dose)
Table 41. Global Meningococcal Vaccine Sales by Company (2021-2026) & (million Dose)
Table 42. Global Meningococcal Vaccine Sales Market Share by Company (2021-2026)
Table 43. Global Meningococcal Vaccine Revenue by Company (2021-2026) & ($ millions)
Table 44. Global Meningococcal Vaccine Revenue Market Share by Company (2021-2026)
Table 45. Global Meningococcal Vaccine Sale Price by Company (2021-2026) & (US$/Dose)
Table 46. Key Manufacturers Meningococcal Vaccine Producing Area Distribution and Sales Area
Table 47. Players Meningococcal Vaccine Products Offered
Table 48. Meningococcal Vaccine Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 49. New Products and Potential Entrants
Table 50. Market M&A Activity & Strategy
Table 51. Global Meningococcal Vaccine Sales by Geographic Region (2021-2026) & (million Dose)
Table 52. Global Meningococcal Vaccine Sales Market Share Geographic Region (2021-2026)
Table 53. Global Meningococcal Vaccine Revenue by Geographic Region (2021-2026) & ($ millions)
Table 54. Global Meningococcal Vaccine Revenue Market Share by Geographic Region (2021-2026)
Table 55. Global Meningococcal Vaccine Sales by Country/Region (2021-2026) & (million Dose)
Table 56. Global Meningococcal Vaccine Sales Market Share by Country/Region (2021-2026)
Table 57. Global Meningococcal Vaccine Revenue by Country/Region (2021-2026) & ($ millions)
Table 58. Global Meningococcal Vaccine Revenue Market Share by Country/Region (2021-2026)
Table 59. Americas Meningococcal Vaccine Sales by Country (2021-2026) & (million Dose)
Table 60. Americas Meningococcal Vaccine Sales Market Share by Country (2021-2026)
Table 61. Americas Meningococcal Vaccine Revenue by Country (2021-2026) & ($ millions)
Table 62. Americas Meningococcal Vaccine Sales by Vaccine Platform (2021-2026) & (million Dose)
Table 63. Americas Meningococcal Vaccine Sales by Application (2021-2026) & (million Dose)
Table 64. APAC Meningococcal Vaccine Sales by Region (2021-2026) & (million Dose)
Table 65. APAC Meningococcal Vaccine Sales Market Share by Region (2021-2026)
Table 66. APAC Meningococcal Vaccine Revenue by Region (2021-2026) & ($ millions)
Table 67. APAC Meningococcal Vaccine Sales by Vaccine Platform (2021-2026) & (million Dose)
Table 68. APAC Meningococcal Vaccine Sales by Application (2021-2026) & (million Dose)
Table 69. Europe Meningococcal Vaccine Sales by Country (2021-2026) & (million Dose)
Table 70. Europe Meningococcal Vaccine Revenue by Country (2021-2026) & ($ millions)
Table 71. Europe Meningococcal Vaccine Sales by Vaccine Platform (2021-2026) & (million Dose)
Table 72. Europe Meningococcal Vaccine Sales by Application (2021-2026) & (million Dose)
Table 73. Middle East & Africa Meningococcal Vaccine Sales by Country (2021-2026) & (million Dose)
Table 74. Middle East & Africa Meningococcal Vaccine Revenue Market Share by Country (2021-2026)
Table 75. Middle East & Africa Meningococcal Vaccine Sales by Vaccine Platform (2021-2026) & (million Dose)
Table 76. Middle East & Africa Meningococcal Vaccine Sales by Application (2021-2026) & (million Dose)
Table 77. Key Market Drivers & Growth Opportunities of Meningococcal Vaccine
Table 78. Key Market Challenges & Risks of Meningococcal Vaccine
Table 79. Key Industry Trends of Meningococcal Vaccine
Table 80. Meningococcal Vaccine Raw Material
Table 81. Key Suppliers of Raw Materials
Table 82. Meningococcal Vaccine Distributors List
Table 83. Meningococcal Vaccine Customer List
Table 84. Global Meningococcal Vaccine Sales Forecast by Region (2027-2032) & (million Dose)
Table 85. Global Meningococcal Vaccine Revenue Forecast by Region (2027-2032) & ($ millions)
Table 86. Americas Meningococcal Vaccine Sales Forecast by Country (2027-2032) & (million Dose)
Table 87. Americas Meningococcal Vaccine Annual Revenue Forecast by Country (2027-2032) & ($ millions)
Table 88. APAC Meningococcal Vaccine Sales Forecast by Region (2027-2032) & (million Dose)
Table 89. APAC Meningococcal Vaccine Annual Revenue Forecast by Region (2027-2032) & ($ millions)
Table 90. Europe Meningococcal Vaccine Sales Forecast by Country (2027-2032) & (million Dose)
Table 91. Europe Meningococcal Vaccine Revenue Forecast by Country (2027-2032) & ($ millions)
Table 92. Middle East & Africa Meningococcal Vaccine Sales Forecast by Country (2027-2032) & (million Dose)
Table 93. Middle East & Africa Meningococcal Vaccine Revenue Forecast by Country (2027-2032) & ($ millions)
Table 94. Global Meningococcal Vaccine Sales Forecast by Vaccine Platform (2027-2032) & (million Dose)
Table 95. Global Meningococcal Vaccine Revenue Forecast by Vaccine Platform (2027-2032) & ($ millions)
Table 96. Global Meningococcal Vaccine Sales Forecast by Application (2027-2032) & (million Dose)
Table 97. Global Meningococcal Vaccine Revenue Forecast by Application (2027-2032) & ($ millions)
Table 98. GSK Basic Information, Meningococcal Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 99. GSK Meningococcal Vaccine Product Portfolios and Specifications
Table 100. GSK Meningococcal Vaccine Sales (million Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 101. GSK Main Business
Table 102. GSK Latest Developments
Table 103. Sanofi Basic Information, Meningococcal Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 104. Sanofi Meningococcal Vaccine Product Portfolios and Specifications
Table 105. Sanofi Meningococcal Vaccine Sales (million Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 106. Sanofi Main Business
Table 107. Sanofi Latest Developments
Table 108. Pfizer Basic Information, Meningococcal Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 109. Pfizer Meningococcal Vaccine Product Portfolios and Specifications
Table 110. Pfizer Meningococcal Vaccine Sales (million Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 111. Pfizer Main Business
Table 112. Pfizer Latest Developments
Table 113. Serum Institute of India Basic Information, Meningococcal Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 114. Serum Institute of India Meningococcal Vaccine Product Portfolios and Specifications
Table 115. Serum Institute of India Meningococcal Vaccine Sales (million Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 116. Serum Institute of India Main Business
Table 117. Serum Institute of India Latest Developments
Table 118. CanSino Biologics Basic Information, Meningococcal Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 119. CanSino Biologics Meningococcal Vaccine Product Portfolios and Specifications
Table 120. CanSino Biologics Meningococcal Vaccine Sales (million Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 121. CanSino Biologics Main Business
Table 122. CanSino Biologics Latest Developments
Table 123. Yuxi Walvax Biotechnology Basic Information, Meningococcal Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 124. Yuxi Walvax Biotechnology Meningococcal Vaccine Product Portfolios and Specifications
Table 125. Yuxi Walvax Biotechnology Meningococcal Vaccine Sales (million Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 126. Yuxi Walvax Biotechnology Main Business
Table 127. Yuxi Walvax Biotechnology Latest Developments
Table 128. Beijing Zhifei Lvzhu Biopharmaceutical Basic Information, Meningococcal Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 129. Beijing Zhifei Lvzhu Biopharmaceutical Meningococcal Vaccine Product Portfolios and Specifications
Table 130. Beijing Zhifei Lvzhu Biopharmaceutical Meningococcal Vaccine Sales (million Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 131. Beijing Zhifei Lvzhu Biopharmaceutical Main Business
Table 132. Beijing Zhifei Lvzhu Biopharmaceutical Latest Developments
Table 133. China National Biotec Group Basic Information, Meningococcal Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 134. China National Biotec Group Meningococcal Vaccine Product Portfolios and Specifications
Table 135. China National Biotec Group Meningococcal Vaccine Sales (million Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 136. China National Biotec Group Main Business
Table 137. China National Biotec Group Latest Developments
Table 138. Funda??o Oswaldo Cruz Basic Information, Meningococcal Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 139. Funda??o Oswaldo Cruz Meningococcal Vaccine Product Portfolios and Specifications
Table 140. Funda??o Oswaldo Cruz Meningococcal Vaccine Sales (million Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 141. Funda??o Oswaldo Cruz Main Business
Table 142. Funda??o Oswaldo Cruz Latest Developments
Table 143. Funda??o Ezequiel Dias Basic Information, Meningococcal Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 144. Funda??o Ezequiel Dias Meningococcal Vaccine Product Portfolios and Specifications
Table 145. Funda??o Ezequiel Dias Meningococcal Vaccine Sales (million Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 146. Funda??o Ezequiel Dias Main Business
Table 147. Funda??o Ezequiel Dias Latest Developments
Table 148. Instituto Finlay de Vacunas Basic Information, Meningococcal Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 149. Instituto Finlay de Vacunas Meningococcal Vaccine Product Portfolios and Specifications
Table 150. Instituto Finlay de Vacunas Meningococcal Vaccine Sales (million Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 151. Instituto Finlay de Vacunas Main Business
Table 152. Instituto Finlay de Vacunas Latest Developments
Table 153. PT Bio Farma Basic Information, Meningococcal Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 154. PT Bio Farma Meningococcal Vaccine Product Portfolios and Specifications
Table 155. PT Bio Farma Meningococcal Vaccine Sales (million Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 156. PT Bio Farma Main Business
Table 157. PT Bio Farma Latest Developments
Table 158. Hualan Biological Bacterin Basic Information, Meningococcal Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 159. Hualan Biological Bacterin Meningococcal Vaccine Product Portfolios and Specifications
Table 160. Hualan Biological Bacterin Meningococcal Vaccine Sales (million Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 161. Hualan Biological Bacterin Main Business
Table 162. Hualan Biological Bacterin Latest Developments
Table 163. Chengdu Olymvax Biopharmaceuticals Basic Information, Meningococcal Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 164. Chengdu Olymvax Biopharmaceuticals Meningococcal Vaccine Product Portfolios and Specifications
Table 165. Chengdu Olymvax Biopharmaceuticals Meningococcal Vaccine Sales (million Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 166. Chengdu Olymvax Biopharmaceuticals Main Business
Table 167. Chengdu Olymvax Biopharmaceuticals Latest Developments
Table 168. Royal Wuxi Bio-Pharmaceutical Basic Information, Meningococcal Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 169. Royal Wuxi Bio-Pharmaceutical Meningococcal Vaccine Product Portfolios and Specifications
Table 170. Royal Wuxi Bio-Pharmaceutical Meningococcal Vaccine Sales (million Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 171. Royal Wuxi Bio-Pharmaceutical Main Business
Table 172. Royal Wuxi Bio-Pharmaceutical Latest Developments
Table 173. AIM Persistence Biopharmaceutical Basic Information, Meningococcal Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 174. AIM Persistence Biopharmaceutical Meningococcal Vaccine Product Portfolios and Specifications
Table 175. AIM Persistence Biopharmaceutical Meningococcal Vaccine Sales (million Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 176. AIM Persistence Biopharmaceutical Main Business
Table 177. AIM Persistence Biopharmaceutical Latest Developments
Table 178. NPO Microgen Basic Information, Meningococcal Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 179. NPO Microgen Meningococcal Vaccine Product Portfolios and Specifications
Table 180. NPO Microgen Meningococcal Vaccine Sales (million Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 181. NPO Microgen Main Business
Table 182. NPO Microgen Latest Developments
Table 183. Incepta Vaccine Basic Information, Meningococcal Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 184. Incepta Vaccine Meningococcal Vaccine Product Portfolios and Specifications
Table 185. Incepta Vaccine Meningococcal Vaccine Sales (million Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 186. Incepta Vaccine Main Business
Table 187. Incepta Vaccine Latest Developments
Table 1. Meningococcal Vaccine Annual Sales CAGR by Geographic Region (2021, 2025 & 2032) & ($ millions)
Table 2. Meningococcal Vaccine Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of Plain Polysaccharide Vaccines
Table 4. Major Players of Conjugate Vaccines
Table 5. Major Players of Recombinant Protein Vaccines
Table 6. Major Players of Multi-Platform Vaccines
Table 7. Global Meningococcal Vaccine Sales by Vaccine Platform (2021-2026) & (million Dose)
Table 8. Global Meningococcal Vaccine Sales Market Share by Vaccine Platform (2021-2026)
Table 9. Global Meningococcal Vaccine Revenue by Vaccine Platform (2021-2026) & ($ million)
Table 10. Global Meningococcal Vaccine Revenue Market Share by Vaccine Platform (2021-2026)
Table 11. Global Meningococcal Vaccine Sale Price by Vaccine Platform (2021-2026) & (US$/Dose)
Table 12. Major Players of MenA Vaccines
Table 13. Major Players of MenB Vaccines
Table 14. Major Players of MenC Vaccines
Table 15. Major Players of MenAC Vaccines
Table 16. Major Players of MenBC Vaccines
Table 17. Major Players of MenACW Vaccines
Table 18. Major Players of MenACWY Vaccines
Table 19. Major Players of MenABCWY Vaccines
Table 20. Major Players of MenACWYX Vaccines
Table 21. Global Meningococcal Vaccine Sales by Serogroup Coverage (2021-2026) & (million Dose)
Table 22. Global Meningococcal Vaccine Sales Market Share by Serogroup Coverage (2021-2026)
Table 23. Global Meningococcal Vaccine Revenue by Serogroup Coverage (2021-2026) & ($ million)
Table 24. Global Meningococcal Vaccine Revenue Market Share by Serogroup Coverage (2021-2026)
Table 25. Global Meningococcal Vaccine Sale Price by Serogroup Coverage (2021-2026) & (US$/Dose)
Table 26. Major Players of Single-Dose Liquid
Table 27. Major Players of Multi-Dose Liquid
Table 28. Major Players of Single-Dose Lyophilized
Table 29. Major Players of Multi-Dose Lyophilized
Table 30. Major Players of Multi-Component Kit
Table 31. Global Meningococcal Vaccine Sales by Presentation (2021-2026) & (million Dose)
Table 32. Global Meningococcal Vaccine Sales Market Share by Presentation (2021-2026)
Table 33. Global Meningococcal Vaccine Revenue by Presentation (2021-2026) & ($ million)
Table 34. Global Meningococcal Vaccine Revenue Market Share by Presentation (2021-2026)
Table 35. Global Meningococcal Vaccine Sale Price by Presentation (2021-2026) & (US$/Dose)
Table 36. Global Meningococcal Vaccine Sale by Application (2021-2026) & (million Dose)
Table 37. Global Meningococcal Vaccine Sale Market Share by Application (2021-2026)
Table 38. Global Meningococcal Vaccine Revenue by Application (2021-2026) & ($ million)
Table 39. Global Meningococcal Vaccine Revenue Market Share by Application (2021-2026)
Table 40. Global Meningococcal Vaccine Sale Price by Application (2021-2026) & (US$/Dose)
Table 41. Global Meningococcal Vaccine Sales by Company (2021-2026) & (million Dose)
Table 42. Global Meningococcal Vaccine Sales Market Share by Company (2021-2026)
Table 43. Global Meningococcal Vaccine Revenue by Company (2021-2026) & ($ millions)
Table 44. Global Meningococcal Vaccine Revenue Market Share by Company (2021-2026)
Table 45. Global Meningococcal Vaccine Sale Price by Company (2021-2026) & (US$/Dose)
Table 46. Key Manufacturers Meningococcal Vaccine Producing Area Distribution and Sales Area
Table 47. Players Meningococcal Vaccine Products Offered
Table 48. Meningococcal Vaccine Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 49. New Products and Potential Entrants
Table 50. Market M&A Activity & Strategy
Table 51. Global Meningococcal Vaccine Sales by Geographic Region (2021-2026) & (million Dose)
Table 52. Global Meningococcal Vaccine Sales Market Share Geographic Region (2021-2026)
Table 53. Global Meningococcal Vaccine Revenue by Geographic Region (2021-2026) & ($ millions)
Table 54. Global Meningococcal Vaccine Revenue Market Share by Geographic Region (2021-2026)
Table 55. Global Meningococcal Vaccine Sales by Country/Region (2021-2026) & (million Dose)
Table 56. Global Meningococcal Vaccine Sales Market Share by Country/Region (2021-2026)
Table 57. Global Meningococcal Vaccine Revenue by Country/Region (2021-2026) & ($ millions)
Table 58. Global Meningococcal Vaccine Revenue Market Share by Country/Region (2021-2026)
Table 59. Americas Meningococcal Vaccine Sales by Country (2021-2026) & (million Dose)
Table 60. Americas Meningococcal Vaccine Sales Market Share by Country (2021-2026)
Table 61. Americas Meningococcal Vaccine Revenue by Country (2021-2026) & ($ millions)
Table 62. Americas Meningococcal Vaccine Sales by Vaccine Platform (2021-2026) & (million Dose)
Table 63. Americas Meningococcal Vaccine Sales by Application (2021-2026) & (million Dose)
Table 64. APAC Meningococcal Vaccine Sales by Region (2021-2026) & (million Dose)
Table 65. APAC Meningococcal Vaccine Sales Market Share by Region (2021-2026)
Table 66. APAC Meningococcal Vaccine Revenue by Region (2021-2026) & ($ millions)
Table 67. APAC Meningococcal Vaccine Sales by Vaccine Platform (2021-2026) & (million Dose)
Table 68. APAC Meningococcal Vaccine Sales by Application (2021-2026) & (million Dose)
Table 69. Europe Meningococcal Vaccine Sales by Country (2021-2026) & (million Dose)
Table 70. Europe Meningococcal Vaccine Revenue by Country (2021-2026) & ($ millions)
Table 71. Europe Meningococcal Vaccine Sales by Vaccine Platform (2021-2026) & (million Dose)
Table 72. Europe Meningococcal Vaccine Sales by Application (2021-2026) & (million Dose)
Table 73. Middle East & Africa Meningococcal Vaccine Sales by Country (2021-2026) & (million Dose)
Table 74. Middle East & Africa Meningococcal Vaccine Revenue Market Share by Country (2021-2026)
Table 75. Middle East & Africa Meningococcal Vaccine Sales by Vaccine Platform (2021-2026) & (million Dose)
Table 76. Middle East & Africa Meningococcal Vaccine Sales by Application (2021-2026) & (million Dose)
Table 77. Key Market Drivers & Growth Opportunities of Meningococcal Vaccine
Table 78. Key Market Challenges & Risks of Meningococcal Vaccine
Table 79. Key Industry Trends of Meningococcal Vaccine
Table 80. Meningococcal Vaccine Raw Material
Table 81. Key Suppliers of Raw Materials
Table 82. Meningococcal Vaccine Distributors List
Table 83. Meningococcal Vaccine Customer List
Table 84. Global Meningococcal Vaccine Sales Forecast by Region (2027-2032) & (million Dose)
Table 85. Global Meningococcal Vaccine Revenue Forecast by Region (2027-2032) & ($ millions)
Table 86. Americas Meningococcal Vaccine Sales Forecast by Country (2027-2032) & (million Dose)
Table 87. Americas Meningococcal Vaccine Annual Revenue Forecast by Country (2027-2032) & ($ millions)
Table 88. APAC Meningococcal Vaccine Sales Forecast by Region (2027-2032) & (million Dose)
Table 89. APAC Meningococcal Vaccine Annual Revenue Forecast by Region (2027-2032) & ($ millions)
Table 90. Europe Meningococcal Vaccine Sales Forecast by Country (2027-2032) & (million Dose)
Table 91. Europe Meningococcal Vaccine Revenue Forecast by Country (2027-2032) & ($ millions)
Table 92. Middle East & Africa Meningococcal Vaccine Sales Forecast by Country (2027-2032) & (million Dose)
Table 93. Middle East & Africa Meningococcal Vaccine Revenue Forecast by Country (2027-2032) & ($ millions)
Table 94. Global Meningococcal Vaccine Sales Forecast by Vaccine Platform (2027-2032) & (million Dose)
Table 95. Global Meningococcal Vaccine Revenue Forecast by Vaccine Platform (2027-2032) & ($ millions)
Table 96. Global Meningococcal Vaccine Sales Forecast by Application (2027-2032) & (million Dose)
Table 97. Global Meningococcal Vaccine Revenue Forecast by Application (2027-2032) & ($ millions)
Table 98. GSK Basic Information, Meningococcal Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 99. GSK Meningococcal Vaccine Product Portfolios and Specifications
Table 100. GSK Meningococcal Vaccine Sales (million Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 101. GSK Main Business
Table 102. GSK Latest Developments
Table 103. Sanofi Basic Information, Meningococcal Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 104. Sanofi Meningococcal Vaccine Product Portfolios and Specifications
Table 105. Sanofi Meningococcal Vaccine Sales (million Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 106. Sanofi Main Business
Table 107. Sanofi Latest Developments
Table 108. Pfizer Basic Information, Meningococcal Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 109. Pfizer Meningococcal Vaccine Product Portfolios and Specifications
Table 110. Pfizer Meningococcal Vaccine Sales (million Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 111. Pfizer Main Business
Table 112. Pfizer Latest Developments
Table 113. Serum Institute of India Basic Information, Meningococcal Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 114. Serum Institute of India Meningococcal Vaccine Product Portfolios and Specifications
Table 115. Serum Institute of India Meningococcal Vaccine Sales (million Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 116. Serum Institute of India Main Business
Table 117. Serum Institute of India Latest Developments
Table 118. CanSino Biologics Basic Information, Meningococcal Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 119. CanSino Biologics Meningococcal Vaccine Product Portfolios and Specifications
Table 120. CanSino Biologics Meningococcal Vaccine Sales (million Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 121. CanSino Biologics Main Business
Table 122. CanSino Biologics Latest Developments
Table 123. Yuxi Walvax Biotechnology Basic Information, Meningococcal Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 124. Yuxi Walvax Biotechnology Meningococcal Vaccine Product Portfolios and Specifications
Table 125. Yuxi Walvax Biotechnology Meningococcal Vaccine Sales (million Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 126. Yuxi Walvax Biotechnology Main Business
Table 127. Yuxi Walvax Biotechnology Latest Developments
Table 128. Beijing Zhifei Lvzhu Biopharmaceutical Basic Information, Meningococcal Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 129. Beijing Zhifei Lvzhu Biopharmaceutical Meningococcal Vaccine Product Portfolios and Specifications
Table 130. Beijing Zhifei Lvzhu Biopharmaceutical Meningococcal Vaccine Sales (million Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 131. Beijing Zhifei Lvzhu Biopharmaceutical Main Business
Table 132. Beijing Zhifei Lvzhu Biopharmaceutical Latest Developments
Table 133. China National Biotec Group Basic Information, Meningococcal Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 134. China National Biotec Group Meningococcal Vaccine Product Portfolios and Specifications
Table 135. China National Biotec Group Meningococcal Vaccine Sales (million Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 136. China National Biotec Group Main Business
Table 137. China National Biotec Group Latest Developments
Table 138. Funda??o Oswaldo Cruz Basic Information, Meningococcal Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 139. Funda??o Oswaldo Cruz Meningococcal Vaccine Product Portfolios and Specifications
Table 140. Funda??o Oswaldo Cruz Meningococcal Vaccine Sales (million Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 141. Funda??o Oswaldo Cruz Main Business
Table 142. Funda??o Oswaldo Cruz Latest Developments
Table 143. Funda??o Ezequiel Dias Basic Information, Meningococcal Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 144. Funda??o Ezequiel Dias Meningococcal Vaccine Product Portfolios and Specifications
Table 145. Funda??o Ezequiel Dias Meningococcal Vaccine Sales (million Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 146. Funda??o Ezequiel Dias Main Business
Table 147. Funda??o Ezequiel Dias Latest Developments
Table 148. Instituto Finlay de Vacunas Basic Information, Meningococcal Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 149. Instituto Finlay de Vacunas Meningococcal Vaccine Product Portfolios and Specifications
Table 150. Instituto Finlay de Vacunas Meningococcal Vaccine Sales (million Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 151. Instituto Finlay de Vacunas Main Business
Table 152. Instituto Finlay de Vacunas Latest Developments
Table 153. PT Bio Farma Basic Information, Meningococcal Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 154. PT Bio Farma Meningococcal Vaccine Product Portfolios and Specifications
Table 155. PT Bio Farma Meningococcal Vaccine Sales (million Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 156. PT Bio Farma Main Business
Table 157. PT Bio Farma Latest Developments
Table 158. Hualan Biological Bacterin Basic Information, Meningococcal Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 159. Hualan Biological Bacterin Meningococcal Vaccine Product Portfolios and Specifications
Table 160. Hualan Biological Bacterin Meningococcal Vaccine Sales (million Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 161. Hualan Biological Bacterin Main Business
Table 162. Hualan Biological Bacterin Latest Developments
Table 163. Chengdu Olymvax Biopharmaceuticals Basic Information, Meningococcal Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 164. Chengdu Olymvax Biopharmaceuticals Meningococcal Vaccine Product Portfolios and Specifications
Table 165. Chengdu Olymvax Biopharmaceuticals Meningococcal Vaccine Sales (million Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 166. Chengdu Olymvax Biopharmaceuticals Main Business
Table 167. Chengdu Olymvax Biopharmaceuticals Latest Developments
Table 168. Royal Wuxi Bio-Pharmaceutical Basic Information, Meningococcal Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 169. Royal Wuxi Bio-Pharmaceutical Meningococcal Vaccine Product Portfolios and Specifications
Table 170. Royal Wuxi Bio-Pharmaceutical Meningococcal Vaccine Sales (million Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 171. Royal Wuxi Bio-Pharmaceutical Main Business
Table 172. Royal Wuxi Bio-Pharmaceutical Latest Developments
Table 173. AIM Persistence Biopharmaceutical Basic Information, Meningococcal Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 174. AIM Persistence Biopharmaceutical Meningococcal Vaccine Product Portfolios and Specifications
Table 175. AIM Persistence Biopharmaceutical Meningococcal Vaccine Sales (million Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 176. AIM Persistence Biopharmaceutical Main Business
Table 177. AIM Persistence Biopharmaceutical Latest Developments
Table 178. NPO Microgen Basic Information, Meningococcal Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 179. NPO Microgen Meningococcal Vaccine Product Portfolios and Specifications
Table 180. NPO Microgen Meningococcal Vaccine Sales (million Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 181. NPO Microgen Main Business
Table 182. NPO Microgen Latest Developments
Table 183. Incepta Vaccine Basic Information, Meningococcal Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 184. Incepta Vaccine Meningococcal Vaccine Product Portfolios and Specifications
Table 185. Incepta Vaccine Meningococcal Vaccine Sales (million Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 186. Incepta Vaccine Main Business
Table 187. Incepta Vaccine Latest Developments
LIST OF FIGURES
Figure 1. Picture of Meningococcal Vaccine
Figure 2. Meningococcal Vaccine Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Meningococcal Vaccine Sales Growth Rate 2021-2032 (million Dose)
Figure 7. Global Meningococcal Vaccine Revenue Growth Rate 2021-2032 ($ millions)
Figure 8. Meningococcal Vaccine Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 9. Meningococcal Vaccine Sales Market Share by Country/Region (2025)
Figure 10. Meningococcal Vaccine Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 11. Product Picture of Plain Polysaccharide Vaccines
Figure 12. Product Picture of Conjugate Vaccines
Figure 13. Product Picture of Recombinant Protein Vaccines
Figure 14. Product Picture of Multi-Platform Vaccines
Figure 15. Global Meningococcal Vaccine Sales Market Share by Vaccine Platform in 2026
Figure 16. Global Meningococcal Vaccine Revenue Market Share by Vaccine Platform (2021-2026)
Figure 17. Product Picture of MenA Vaccines
Figure 18. Product Picture of MenB Vaccines
Figure 19. Product Picture of MenC Vaccines
Figure 20. Product Picture of MenAC Vaccines
Figure 21. Product Picture of MenBC Vaccines
Figure 22. Product Picture of MenACW Vaccines
Figure 23. Product Picture of MenACWY Vaccines
Figure 24. Product Picture of MenABCWY Vaccines
Figure 25. Product Picture of MenACWYX Vaccines
Figure 26. Global Meningococcal Vaccine Sales Market Share by Serogroup Coverage in 2026
Figure 27. Global Meningococcal Vaccine Revenue Market Share by Serogroup Coverage (2021-2026)
Figure 28. Product Picture of Single-Dose Liquid
Figure 29. Product Picture of Multi-Dose Liquid
Figure 30. Product Picture of Single-Dose Lyophilized
Figure 31. Product Picture of Multi-Dose Lyophilized
Figure 32. Product Picture of Multi-Component Kit
Figure 33. Global Meningococcal Vaccine Sales Market Share by Presentation in 2026
Figure 34. Global Meningococcal Vaccine Revenue Market Share by Presentation (2021-2026)
Figure 35. Meningococcal Vaccine Consumed in Routine Pediatric Immunization
Figure 36. Global Meningococcal Vaccine Market: Routine Pediatric Immunization (2021-2026) & (million Dose)
Figure 37. Meningococcal Vaccine Consumed in Routine Adolescent Immunization
Figure 38. Global Meningococcal Vaccine Market: Routine Adolescent Immunization (2021-2026) & (million Dose)
Figure 39. Meningococcal Vaccine Consumed in Preventive Mass Campaigns
Figure 40. Global Meningococcal Vaccine Market: Preventive Mass Campaigns (2021-2026) & (million Dose)
Figure 41. Meningococcal Vaccine Consumed in Outbreak Response
Figure 42. Global Meningococcal Vaccine Market: Outbreak Response (2021-2026) & (million Dose)
Figure 43. Meningococcal Vaccine Consumed in High-Risk Clinical Immunization
Figure 44. Global Meningococcal Vaccine Market: High-Risk Clinical Immunization (2021-2026) & (million Dose)
Figure 45. Meningococcal Vaccine Consumed in Travel Immunization
Figure 46. Global Meningococcal Vaccine Market: Travel Immunization (2021-2026) & (million Dose)
Figure 47. Meningococcal Vaccine Consumed in Institutional Immunization
Figure 48. Global Meningococcal Vaccine Market: Institutional Immunization (2021-2026) & (million Dose)
Figure 49. Meningococcal Vaccine Consumed in Occupational Immunization
Figure 50. Global Meningococcal Vaccine Market: Occupational Immunization (2021-2026) & (million Dose)
Figure 51. Meningococcal Vaccine Consumed in Catch-Up Immunization
Figure 52. Global Meningococcal Vaccine Market: Catch-Up Immunization (2021-2026) & (million Dose)
Figure 53. Global Meningococcal Vaccine Sale Market Share by Application (2025)
Figure 54. Global Meningococcal Vaccine Revenue Market Share by Application in 2025
Figure 55. Meningococcal Vaccine Sales by Company in 2025 (million Dose)
Figure 56. Global Meningococcal Vaccine Sales Market Share by Company in 2025
Figure 57. Meningococcal Vaccine Revenue by Company in 2025 ($ millions)
Figure 58. Global Meningococcal Vaccine Revenue Market Share by Company in 2025
Figure 59. Global Meningococcal Vaccine Sales Market Share by Geographic Region (2021-2026)
Figure 60. Global Meningococcal Vaccine Revenue Market Share by Geographic Region in 2025
Figure 61. Americas Meningococcal Vaccine Sales 2021-2026 (million Dose)
Figure 62. Americas Meningococcal Vaccine Revenue 2021-2026 ($ millions)
Figure 63. APAC Meningococcal Vaccine Sales 2021-2026 (million Dose)
Figure 64. APAC Meningococcal Vaccine Revenue 2021-2026 ($ millions)
Figure 65. Europe Meningococcal Vaccine Sales 2021-2026 (million Dose)
Figure 66. Europe Meningococcal Vaccine Revenue 2021-2026 ($ millions)
Figure 67. Middle East & Africa Meningococcal Vaccine Sales 2021-2026 (million Dose)
Figure 68. Middle East & Africa Meningococcal Vaccine Revenue 2021-2026 ($ millions)
Figure 69. Americas Meningococcal Vaccine Sales Market Share by Country in 2025
Figure 70. Americas Meningococcal Vaccine Revenue Market Share by Country (2021-2026)
Figure 71. Americas Meningococcal Vaccine Sales Market Share by Vaccine Platform (2021-2026)
Figure 72. Americas Meningococcal Vaccine Sales Market Share by Application (2021-2026)
Figure 73. United States Meningococcal Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 74. Canada Meningococcal Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 75. Mexico Meningococcal Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 76. Brazil Meningococcal Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 77. APAC Meningococcal Vaccine Sales Market Share by Region in 2025
Figure 78. APAC Meningococcal Vaccine Revenue Market Share by Region (2021-2026)
Figure 79. APAC Meningococcal Vaccine Sales Market Share by Vaccine Platform (2021-2026)
Figure 80. APAC Meningococcal Vaccine Sales Market Share by Application (2021-2026)
Figure 81. China Meningococcal Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 82. Japan Meningococcal Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 83. South Korea Meningococcal Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 84. Southeast Asia Meningococcal Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 85. India Meningococcal Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 86. Australia Meningococcal Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 87. China Taiwan Meningococcal Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 88. Europe Meningococcal Vaccine Sales Market Share by Country in 2025
Figure 89. Europe Meningococcal Vaccine Revenue Market Share by Country (2021-2026)
Figure 90. Europe Meningococcal Vaccine Sales Market Share by Vaccine Platform (2021-2026)
Figure 91. Europe Meningococcal Vaccine Sales Market Share by Application (2021-2026)
Figure 92. Germany Meningococcal Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 93. France Meningococcal Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 94. UK Meningococcal Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 95. Italy Meningococcal Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 96. Russia Meningococcal Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 97. Middle East & Africa Meningococcal Vaccine Sales Market Share by Country (2021-2026)
Figure 98. Middle East & Africa Meningococcal Vaccine Sales Market Share by Vaccine Platform (2021-2026)
Figure 99. Middle East & Africa Meningococcal Vaccine Sales Market Share by Application (2021-2026)
Figure 100. Egypt Meningococcal Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 101. South Africa Meningococcal Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 102. Israel Meningococcal Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 103. Turkey Meningococcal Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 104. GCC Countries Meningococcal Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 105. Manufacturing Cost Structure Analysis of Meningococcal Vaccine in 2026
Figure 106. Manufacturing Process Analysis of Meningococcal Vaccine
Figure 107. Industry Chain Structure of Meningococcal Vaccine
Figure 108. Channels of Distribution
Figure 109. Global Meningococcal Vaccine Sales Market Forecast by Region (2027-2032)
Figure 110. Global Meningococcal Vaccine Revenue Market Share Forecast by Region (2027-2032)
Figure 111. Global Meningococcal Vaccine Sales Market Share Forecast by Vaccine Platform (2027-2032)
Figure 112. Global Meningococcal Vaccine Revenue Market Share Forecast by Vaccine Platform (2027-2032)
Figure 113. Global Meningococcal Vaccine Sales Market Share Forecast by Application (2027-2032)
Figure 114. Global Meningococcal Vaccine Revenue Market Share Forecast by Application (2027-2032)
Figure 1. Picture of Meningococcal Vaccine
Figure 2. Meningococcal Vaccine Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Meningococcal Vaccine Sales Growth Rate 2021-2032 (million Dose)
Figure 7. Global Meningococcal Vaccine Revenue Growth Rate 2021-2032 ($ millions)
Figure 8. Meningococcal Vaccine Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 9. Meningococcal Vaccine Sales Market Share by Country/Region (2025)
Figure 10. Meningococcal Vaccine Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 11. Product Picture of Plain Polysaccharide Vaccines
Figure 12. Product Picture of Conjugate Vaccines
Figure 13. Product Picture of Recombinant Protein Vaccines
Figure 14. Product Picture of Multi-Platform Vaccines
Figure 15. Global Meningococcal Vaccine Sales Market Share by Vaccine Platform in 2026
Figure 16. Global Meningococcal Vaccine Revenue Market Share by Vaccine Platform (2021-2026)
Figure 17. Product Picture of MenA Vaccines
Figure 18. Product Picture of MenB Vaccines
Figure 19. Product Picture of MenC Vaccines
Figure 20. Product Picture of MenAC Vaccines
Figure 21. Product Picture of MenBC Vaccines
Figure 22. Product Picture of MenACW Vaccines
Figure 23. Product Picture of MenACWY Vaccines
Figure 24. Product Picture of MenABCWY Vaccines
Figure 25. Product Picture of MenACWYX Vaccines
Figure 26. Global Meningococcal Vaccine Sales Market Share by Serogroup Coverage in 2026
Figure 27. Global Meningococcal Vaccine Revenue Market Share by Serogroup Coverage (2021-2026)
Figure 28. Product Picture of Single-Dose Liquid
Figure 29. Product Picture of Multi-Dose Liquid
Figure 30. Product Picture of Single-Dose Lyophilized
Figure 31. Product Picture of Multi-Dose Lyophilized
Figure 32. Product Picture of Multi-Component Kit
Figure 33. Global Meningococcal Vaccine Sales Market Share by Presentation in 2026
Figure 34. Global Meningococcal Vaccine Revenue Market Share by Presentation (2021-2026)
Figure 35. Meningococcal Vaccine Consumed in Routine Pediatric Immunization
Figure 36. Global Meningococcal Vaccine Market: Routine Pediatric Immunization (2021-2026) & (million Dose)
Figure 37. Meningococcal Vaccine Consumed in Routine Adolescent Immunization
Figure 38. Global Meningococcal Vaccine Market: Routine Adolescent Immunization (2021-2026) & (million Dose)
Figure 39. Meningococcal Vaccine Consumed in Preventive Mass Campaigns
Figure 40. Global Meningococcal Vaccine Market: Preventive Mass Campaigns (2021-2026) & (million Dose)
Figure 41. Meningococcal Vaccine Consumed in Outbreak Response
Figure 42. Global Meningococcal Vaccine Market: Outbreak Response (2021-2026) & (million Dose)
Figure 43. Meningococcal Vaccine Consumed in High-Risk Clinical Immunization
Figure 44. Global Meningococcal Vaccine Market: High-Risk Clinical Immunization (2021-2026) & (million Dose)
Figure 45. Meningococcal Vaccine Consumed in Travel Immunization
Figure 46. Global Meningococcal Vaccine Market: Travel Immunization (2021-2026) & (million Dose)
Figure 47. Meningococcal Vaccine Consumed in Institutional Immunization
Figure 48. Global Meningococcal Vaccine Market: Institutional Immunization (2021-2026) & (million Dose)
Figure 49. Meningococcal Vaccine Consumed in Occupational Immunization
Figure 50. Global Meningococcal Vaccine Market: Occupational Immunization (2021-2026) & (million Dose)
Figure 51. Meningococcal Vaccine Consumed in Catch-Up Immunization
Figure 52. Global Meningococcal Vaccine Market: Catch-Up Immunization (2021-2026) & (million Dose)
Figure 53. Global Meningococcal Vaccine Sale Market Share by Application (2025)
Figure 54. Global Meningococcal Vaccine Revenue Market Share by Application in 2025
Figure 55. Meningococcal Vaccine Sales by Company in 2025 (million Dose)
Figure 56. Global Meningococcal Vaccine Sales Market Share by Company in 2025
Figure 57. Meningococcal Vaccine Revenue by Company in 2025 ($ millions)
Figure 58. Global Meningococcal Vaccine Revenue Market Share by Company in 2025
Figure 59. Global Meningococcal Vaccine Sales Market Share by Geographic Region (2021-2026)
Figure 60. Global Meningococcal Vaccine Revenue Market Share by Geographic Region in 2025
Figure 61. Americas Meningococcal Vaccine Sales 2021-2026 (million Dose)
Figure 62. Americas Meningococcal Vaccine Revenue 2021-2026 ($ millions)
Figure 63. APAC Meningococcal Vaccine Sales 2021-2026 (million Dose)
Figure 64. APAC Meningococcal Vaccine Revenue 2021-2026 ($ millions)
Figure 65. Europe Meningococcal Vaccine Sales 2021-2026 (million Dose)
Figure 66. Europe Meningococcal Vaccine Revenue 2021-2026 ($ millions)
Figure 67. Middle East & Africa Meningococcal Vaccine Sales 2021-2026 (million Dose)
Figure 68. Middle East & Africa Meningococcal Vaccine Revenue 2021-2026 ($ millions)
Figure 69. Americas Meningococcal Vaccine Sales Market Share by Country in 2025
Figure 70. Americas Meningococcal Vaccine Revenue Market Share by Country (2021-2026)
Figure 71. Americas Meningococcal Vaccine Sales Market Share by Vaccine Platform (2021-2026)
Figure 72. Americas Meningococcal Vaccine Sales Market Share by Application (2021-2026)
Figure 73. United States Meningococcal Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 74. Canada Meningococcal Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 75. Mexico Meningococcal Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 76. Brazil Meningococcal Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 77. APAC Meningococcal Vaccine Sales Market Share by Region in 2025
Figure 78. APAC Meningococcal Vaccine Revenue Market Share by Region (2021-2026)
Figure 79. APAC Meningococcal Vaccine Sales Market Share by Vaccine Platform (2021-2026)
Figure 80. APAC Meningococcal Vaccine Sales Market Share by Application (2021-2026)
Figure 81. China Meningococcal Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 82. Japan Meningococcal Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 83. South Korea Meningococcal Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 84. Southeast Asia Meningococcal Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 85. India Meningococcal Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 86. Australia Meningococcal Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 87. China Taiwan Meningococcal Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 88. Europe Meningococcal Vaccine Sales Market Share by Country in 2025
Figure 89. Europe Meningococcal Vaccine Revenue Market Share by Country (2021-2026)
Figure 90. Europe Meningococcal Vaccine Sales Market Share by Vaccine Platform (2021-2026)
Figure 91. Europe Meningococcal Vaccine Sales Market Share by Application (2021-2026)
Figure 92. Germany Meningococcal Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 93. France Meningococcal Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 94. UK Meningococcal Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 95. Italy Meningococcal Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 96. Russia Meningococcal Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 97. Middle East & Africa Meningococcal Vaccine Sales Market Share by Country (2021-2026)
Figure 98. Middle East & Africa Meningococcal Vaccine Sales Market Share by Vaccine Platform (2021-2026)
Figure 99. Middle East & Africa Meningococcal Vaccine Sales Market Share by Application (2021-2026)
Figure 100. Egypt Meningococcal Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 101. South Africa Meningococcal Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 102. Israel Meningococcal Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 103. Turkey Meningococcal Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 104. GCC Countries Meningococcal Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 105. Manufacturing Cost Structure Analysis of Meningococcal Vaccine in 2026
Figure 106. Manufacturing Process Analysis of Meningococcal Vaccine
Figure 107. Industry Chain Structure of Meningococcal Vaccine
Figure 108. Channels of Distribution
Figure 109. Global Meningococcal Vaccine Sales Market Forecast by Region (2027-2032)
Figure 110. Global Meningococcal Vaccine Revenue Market Share Forecast by Region (2027-2032)
Figure 111. Global Meningococcal Vaccine Sales Market Share Forecast by Vaccine Platform (2027-2032)
Figure 112. Global Meningococcal Vaccine Revenue Market Share Forecast by Vaccine Platform (2027-2032)
Figure 113. Global Meningococcal Vaccine Sales Market Share Forecast by Application (2027-2032)
Figure 114. Global Meningococcal Vaccine Revenue Market Share Forecast by Application (2027-2032)
